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ABSTRACT
Background: The predictors of poor prognosis in patients with coronavirus disease 2019 
(COVID-19) using computed tomography (CT) have not been investigated in a large cohort. 
Therefore, the purpose of this study was to investigate the adverse initial CT features to 
predict poor prognosis in COVID-19.
Methods: From February to April 2020, 281 COVID-19 patients who underwent CT at the 
time of admission were included. We divided the patients into the severe and non-severe 
disease groups. The severe group included patients with severe pneumonia or critical events. 
Intensive care unit admission or death were the critical events in this study. We compared 
the clinical and CT findings between the severe and non-severe groups and investigated the 
prognostic factors and critical events of the severe group using the regression analysis.
Results: Among the 281 patients, 36 (12.8%) patients were in the severe group and 245 
(87.2%) patients were in the non-severe group. Critical events occurred in 10 patients (3.6%). 
In the severe group, patients showed significantly more pneumonia with consolidation, 
crazy-paving appearance, pleural effusion, and higher CT scores than those in the non-severe 
group (all, P < 0.05). In the multivariate regression, pleural effusion (odds ratio [OR], 8.96; 
95% confidence interval [CI], 1.81–44.42; P = 0.007), CT score > 5 (OR, 3.70; 95% CI, 1.44–
9.53; P = 0.007), old age (> 77 years, OR, 9.96; 95% CI, 3.78–26.28; P < 0.001), and elevated 
C-reactive protein (OR, 4.15; 95% CI, 1.62–10.6; P = 0.003) were significant prognostic 
factors of severe disease. CT score > 5 (OR, 7.29; 95% CI, 1.37–38.68; P = 0.020), pleural 
effusion (OR, 5.67; 95% CI, 1.04–30.8; P = 0.045) and old age (OR, 8.6; 95% CI, 1.80–41.0; P 
= 0.007) were also significant predictors of critical events.
Conclusion: Pleural effusion and the extent of pneumonia on initial CT scans are associated 
with poor prognosis in patients with COVID-19.
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INTRODUCTION
In December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first 
identified in Wuhan, China. Since then, the novel coronavirus disease 2019 (COVID-19) 
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rapidly spread to neighboring countries. On March 11, 2020, the World Health Organization 
(WHO) formally declared the COVID-19 outbreak a pandemic.1 As of May 20, 2020, 4,892,550 
people have been infected worldwide, and 322,821 people have died.2 Patients with COVID-19 
are often asymptomatic or mildly symptomatic, however, some of the patients progress to 
develop severe pneumonia and need oxygen treatments. They may also be admitted to the 
intensive care unit (ICU), requiring ventilator care, or they may even die from the disease. 
Therefore, it is a challenge to effectively triage patients in this emergent pandemic situation. 
Recent studies reported clinical findings including older age, underlying disease, and 
elevated inflammatory blood markers as risk factors for poor prognosis in COVID-19.3,4 
Currently, chest computed tomography (CT) scans are not recommended for primary 
screening or diagnosis because of their low positive predictive value (1.5%–30.7%).5-7 The 
Fleischner Society states that imaging could be of help to rapidly triage COVID-19 patients 
with worsening respiratory symptoms in resource-constrained environments.5 If imaging, 
particularly an initial CT, can predict the severity of COVID-19, it may help to rapidly triage 
COVID-19 patients in a resource-constrained setting. Several recent studies reported imaging 
findings of patients with adverse outcomes.8-10 However, there are insufficient studies on the 
radiologic features that predict poor prognosis. Therefore, the purpose of this study was to 
investigate the adverse initial CT features to predict poor prognosis in COVID-19.
METHODS
Patients
We included confirmed COVID-19 patients diagnosed through real time polymerase 
chain reaction admitted in our hospital, with CT scans taken within the first week of 
hospitalization. Exclusion criterion was patients with no CT or patients who had severe 
pneumonia before performing the CT scan.
Among 709 patients admitted in the COVID-19 hospital cohort between February 22, 2020 
and April 3, 2020, 347 patients underwent chest CT (Fig. 1) within one week of admission. 
We excluded 66 patients who already exhibited severe pneumonia when undergoing CT 
scan. Demographic data, underlying diseases, symptom type, date of symptom onset and 
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347 COVID-19 patients
who taken CT at the time of admission
Total 281 patients included in this study
66 patients excluded due to
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Fig. 1. Flow chart of the patient population. 
COVID-19 = coronavirus disease 2019, CT = computed tomography, ICU = intensive care unit.
diagnosis, and initial laboratory findings (complete blood count with differential, C-reactive 
protein [CRP], lactate dehydrogenase [LDH]) were reviewed.
We divided the patients into two groups based on clinical criteria, namely, severe and 
non-severe groups. The inclusion criteria for the severe group was 1) severe pneumonia 
according to the WHO criteria11 (fever or suspected respiratory infection plus one of the 
following: respiratory rate > 30 breaths/min, severe respiratory distress, or peripheral oxygen 
saturation ≤ 93% on room air), 2) admitted to the ICU, 3) or death due to COVID-19. In this 
study, the critical events were admission to the ICU and death. COVID-19 patients who did 
not progress to severe pneumonia were included in the non-severe group. Among the 281 
included patients, three patients had an unknown medical history, and the symptom type 
was unknown in two patients due to difficulties in communication.
Chest CT protocol
The study was conducted in a COVID-19 cohort hospital, the whole hospital area was 
designated as an isolation zone. Radiographers wore personal protective equipment to 
enter the hospital for CT scanning. Chest CT was performed using 128-slice dual-source 
CTs (Definition Flash; Siemens, Munich, Germany). The parameters for the CT were: tube 
voltage, 120 kVp; tube current, reference 60 mAs, with automatic exposure control; slice 
thickness 1.0 mm; and filter b50f. CT images were obtained in the supine position without 
contrast enhancement. The scan range was from the inferior neck to both adrenal glands.
Image analysis
Two radiologists (3 years and 9 years of experience) reviewed the chest CT independently 
in a blinded manner. The presence of increased opacity (ground glass opacity [GGO], 
consolidation, or mixed GGO and consolidation), crazy-paving appearance of lesion, 
distribution of lesions, effusion, extent (location and number of involved lobes or segments), 
and presence of atypical findings (nodules, halo sign, reverse halo sign) were reviewed. 
Peripheral distribution was diagnosed when the pneumonia in the outer one-third was 
greater than that in the inner two-third of the lung.12 The amount of pleural effusion was 
estimated using the anteroposterior (AP) quartile method.13 According to the method, the 
first AP-quartile effusion is considered small, second AP-quartile effusion is moderate, and 
third or fourth AP-quartile effusion is large. In the cases of inter-reader discrepancies, a 
consensus was reached through discussion. We used the CT score recommended by Yang et 
al.14 According to the anatomical structure, both lungs were divided into 20 segments (left 
apicoposterior segment subdivided into the apical and posterior segments, left anteromedial 
basal segment subdivided into the anterior basal and medial basal segments). The lung 
opacity in 20 segments were visually evaluated and scored as 0 (no involvement), 1 (less than 
50% involvement), and 2 (more than 50% involvements), and the scores were summed up. 
The total score was ranging from 0 to 40.14
Statistical analysis
Categorical variables were presented in percentage numbers, and continuous variables were 
presented as means with standard deviations or medians with 25th to 75th percentiles. 
Differences between the two groups were analyzed using the χ2 or Fisher's exact tests 
for categorical variables. The Student's t-test or Mann-Whitney U test were used for 
continuous variables. Interobserver agreement was evaluated using intraclass correlation 
coefficients (ICCs) for continuous variables. The cut-off values of continuous variables 
were set by receiver operating characteristic curve analysis for the severe group. Univariate 
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and multivariate logistic regressions were used to investigate the prognostic factors of the 
severe group and the critical events. In the multivariate analysis, we selected four variables 
to predict the severe group according to the rule of thumb, that is, ten events per variables.15 
We selected three variables to predict critical events. Because, there were four CT factors, 
we divided them into two categories as follows: factors not related to the appearance of 
pneumonia (model 1): CT score and pleural effusion; and factors related to the appearance 
of pneumonia (model 2): consolidation opacity and crazy-paving appearance. Additional 
clinical variables were entered by assessing goodness of fit in a regression model. Therefore, 
age and CRP were entered to investigate prognostic factors of the severe group, and age 
was entered to investigate prognostic factors of critical events in the multivariate regression 
analysis. P values < 0.05 were considered statistically significant. Statistical analyses were 
performed using MedCalc 19.2.1 (Ostend, Ostend, Belgium).
Ethics statement
This retrospective cohort study was approved by the Institutional Review Board of the 




A total of 281 patients (mean age: 61.5 years, 75 male/206 female) were included in this 
study. There were more female patients (206/75, 73.3%) in this cohort. Of them, 36 patients 
(12.8%) were classified into the severe group and 245 patients (87.2%) were classified into 
the non-severe group (Fig. 1). Among the 36 patients in the severe group, 5 patients (13.9%) 
were admitted to the ICU and 5 patients (13.9%) died because of worsening of COVID-19 
pneumonia. The clinical characteristics of the severe and non-severe groups are summarized 
in Table 1. Patients in the severe group were significantly older than those in the non-severe 
group (median age 78 years vs. 60 years, respectively, P < 0.001). Fever was significantly 
more common in the severe group than in the non-severe group (P = 0.001). However other 
symptoms were not significantly different between the two groups (P > 0.05). Patients in the 
severe group had significantly more underlying diseases such as hypertension, cardiovascular 
disease, neurologic disease and malignancy, than those in the non-severe group (all, P < 
0.05). Patients in the severe group showed a higher white blood cell count, higher absolute 
neutrophil count, lower absolute lymphocyte count (ALC), higher CRP, and higher LDH than 
non-severe patients (all, P < 0.05).
CT findings of severe and non-severe COVID-19 patients
The CT findings are summarized in Table 2. The chest CT was taken in a median of one 
day (25th to 75th percentile, 0–1 day) after admission and median of 7 days (25th to 75th 
percentile, 2–13 days) after symptom onset. There was no significant difference in the time 
intervals from the symptom onset to CT scan for the severe and non-severe groups (severe 
group: median 6 days vs. non-severe group: 7 days, P = 0.104). In the severe group, patients 
progressed to severe pneumonia in median 2 days (25th to 75th percentile, 1–5 days) after 
the CT scan, and critical events (ICU admission and death) occurred after a median of 6.6 
days (25th to 75th percentile, 3–6 days) after the CT scan. In the non-severe patients, 36.7% 
of patients had no abnormalities on the CT scans, while only 8.3% in the severe group had 
no abnormalities. Pneumonia with only GGO opacity was not significantly different between 
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the two groups (P = 0.202). Pneumonia which only showed consolidation (Fig. 2) was rare 
(1.1%) and mainly mixed with GGO (30.6%). Mixed consolidation and GGO opacity (50.0% 
vs. 27.8%, P = 0.007), crazy-paving appearance (38.9% vs. 15.9%, P = 0.001) and pleural 
effusion (27.8% vs. 1.2%, P < 0.001) (Figs. 3-5) were significantly more frequent in the severe 
group. Most pleural effusions (10/13, 76.9%) were small in quantity. The number of involved 
lobes and segments were significantly higher in the severe group (3.5 lobes vs. 1 lobe, and 
8 segments vs. 2 segments, both P < 0.001). The CT scores were also significantly higher in 
the severe group (median 9 score vs. 2 score, P < 0.001). The right lower lobe was the most 
frequently (52% in the total population) involved lobe in COVID-19 pneumonia. Pneumonia 
was commonly observed as a peripheral (53.4%), posterior (42.3%) and lower lobe (46.3%) 
distributed pattern. The ICC for CT score was excellent (ICC: 0.994; 95% CI, 0.992–0.995). 
Among the 188 CT scans with abnormalities, there were 14 discrepant between readers, and 
consensus was achieved by reviewing the cases in conjunction.
Prognostic imaging and clinical factor for severe COVID-19
The results of the univariate and multivariate regression analyses to investigate the 
prognostic factors are summarized in Table 3. In the univariate logistic regression, CT 
findings including pleural effusion (odds ratio [OR], 22.03; 95% confidence interval [CI], 
5.64–86.06; P < 0.001), consolidation opacity (OR, 2.34; 95% CI, 1.15–4.76; P = 0.019), 
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Table 1. Clinical characteristics of coronavirus disease patients
Clinical variables Total (n = 281) Non-severe patients (n = 245) Severe patients (n = 36) P value
Sex, male/female 75/206 67/178 8/28 0.516
Age, yr 61.5 (50–72) 60 (49–70) 78 (66–84.75) < 0.001
Symptom typea
Fever 82 (29.4) 63 (25.9) 19 (52.8) 0.001
Chillness 50 (17.9) 41 (16.9) 9 (25.0) 0.235
Cough 107 (38.4) 95 (39.1) 12 (33.3) 0.507
Sputum 80 (28.7) 68 (28.0) 12 (33.3) 0.508
Rhinorrhea 35 (12.5) 30 (12.3) 5 (13.9) 0.788
Sore throat 58 (20.8) 49 (20.2) 9 (25.0) 0.505
Myalgia 74 (26.5) 63 (25.9) 11 (30.6) 0.557
Headache 60 (21.5) 54 (22.2) 6 (16.7) 0.449
Diarrhea 42 (15.1) 37 (15.2) 5 (13.9) 0.834
Dyspnea 46 (16.5) 40 (16.5) 6 (16.7) 0.975
Chest pain 8 (2.9) 6 (2.5) 2 (5.6) 0.276
Underlying diseaseb
Hypertension 85 (30.6) 64 (26.4) 21 (58.3) < 0.001
Diabetes 54 (19.4) 43 (17.8) 11 (30.6) 0.070
Hyperlipidemia 29 (10.4) 26 (10.7) 3 (8.3) > 0.999
Chronic lung disease 17 (6.1) 14 (5.8) 3 (8.3) 0.469
Cardiovascular disease 21 (7.6) 15 (6.2) 6 (16.7) 0.039
Neurologic disease 27 (9.7) 15 (6.2) 12 (33.3) < 0.001
Chronic liver disease 5 (1.8) 4 (1.7) 1 (2.8) 0.503
Chronic kidney disease 2 (0.7) 1 (0.4) 1 (2.8) 0.243
Autoimmune disease 1 (0.4) 1 (0.4) 0 (0.0) > 0.999
Malignancy 16 (5.8) 11 (4.5) 5 (13.9) 0.041
Laboratory findings
WBC count, × 103/µL 5,200 (4,075–6,292.5) 5,190 (4,060–6,200) 5,680 (3,975–6,462.5) 0.548
Absolute neutrophil count, µL 2,970 (2,215–3,982.5) 2,890 (2,180–3,770) 3,945 (2,437.5–4,790) 0.007
Absolute lymphocyte count, cells/µL 1,510 (1,167.5–1,935) 1,570 (1,195–1,995) 1,200 (885–1,535) < 0.001
CRP, mg/dL 0.2 (0.1–1.0) 0.1 (0.03–0.8) 2.7 (4.25–8.925) < 0.001
LDH, U/L 424 (368.5–500) 416 (364–482) 511 (420.5–737.5) < 0.001
Data are presented as the number of patients (%) and median (25th–75th percentile).
WBC = white blood cell, CRP = C-reactive protein, LDH = lactate dehydrogenase.
aUnable to know the symptom type in two patients; bUnable to know the underlying disease history in three patients.
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Table 2. Comparison of chest CT findings of coronavirus disease patients between two groups
CT findings Total (n = 281) Non-severe patients (n = 245) Severe patients (n = 36) P value
No abnormality on CT 93 (33.1) 90 (36.7) 3 (8.3) 0.001
Abnormality on CT 188 (66.9) 155 (63.3) 33 (91.7) 0.001
Opacity
GGO only 91 (32.4) 76 (31.0) 15 (41.7) 0.202
Consolidation only 3 (1.1) 3 (1.2) 0 (0.0) > 0.999
Mixed consolidation and GGO 86 (30.6) 68 (27.8) 18 (50.0) 0.007
Specific findings
Crazy-paving appearance 53 (18.9) 39 (15.9) 14 (38.9) 0.001
Subpleural lines 30 (10.7) 27 (11.0) 3 (8.3) 0.779
Subpleural sparing pattern 93 (33.1) 76 (31.0) 17 (47.2) 0.054
Pleural effusion 13 (4.6) 3 (1.2) 10 (27.8) < 0.001
Atypical findings
Nodule 29 (10.3) 24 (9.8)a 5 (13.9) 0.393
Halo sign 6 (2.1) 6 (2.4) 0 (0.0) > 0.999
Reverse halo sign 19 (6.8) 15 (6.1) 4 (11.1) 0.281
Distribution
Lower lobe predominant 130 (46.3) 109 (44.5) 21 (58.3) 0.120
Upper lobe predominant 18 (6.4) 15 (6.1) 3 (8.3) 0.712
Similar lower and upper lobe distribution 32 (11.4) 24 (9.8) 8 (22.2) 0.044
Peripheral predominant 150 (53.4) 124 (50.6) 26 (72.2) 0.015
Posterior predominant 119 (42.3) 99 (40.4) 20 (55.6) 0.086
Total No. of lobe involvement 1 (0–4) 1 (0–3) 3.5 (1–5) < 0.001
RUL 100 (35.6) 77 (31.4) 23 (63.9) < 0.001
RML 84 (29.9) 65 (26.5) 19 (52.8) 0.001
RLL 146 (52.0) 118 (48.2) 28 (77.8) 0.001
LUL 93 (33.1) 71 (29.0) 22 (61.1) < 0.001
LLL 130 (46.3) 106 (43.3) 24 (66.7) 0.009
Total No. of segment involvement, 0–20 2 (0–8) 2 (0–7) 8 (2.5–16) < 0.001
CT score, 0–40 2 (0–9) 2 (0–7) 9 (2.5–20.5) < 0.001
Single lobe involvement 55 (19.6) 48 (19.6) 7 (19.4) 0.983
Single lesion 22 (7.8) 18 (7.3) 4 (11.1) 0.501
Data are presented as the number of patients (%) or median (25th–75th percentile).
CT = computed tomography, GGO = ground glass opacity, RUL = right upper lobe, RML = right middle lobe, RLL = right lower lobe, LUL = left upper lobe, LLL = 
left lower lobe.
aAmong 24 non-severe patients, 8 patients showed a nodule only without consolidation or GGO, and the remaining 16 patients showed both nodules and 
consolidation or GGO.
Fig. 2. A 54-year-old male patient with non-severe COVID-19 pneumonia. He had a history of hypertension and 
ischemic heart disease. Initial chest computed tomography taken one day after admission (arrow) shows a focal 
peripheral consolidation at both lower lobes. Three segments were involved, and the CT score was 5. There is no 
pleural effusion. During hospitalization, peripheral oxygen saturation was maintained above 95%. 
COVID-19 = coronavirus disease 2019, CT = computed tomography.
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BA
Fig. 3. An 81-year-old female with COVID-19 in the intensive care unit. She had a history of stroke. Initial chest CT one day after admission (A) shows focal GGO at 
the superior segment of the left lower lobe and the right lower lobe (black arrows), and a small amount of left pleural effusion (B; white arrow). Two segments 
were involved, and the CT score was 2. Five days after the initial CT, chest radiograph (C) shows an aggravation of the pneumonia. The peripheral oxygen 
saturation decreased to 88%, and oxygen supply treatment was started. The patient was admitted to the intensive care unit for close monitoring. Follow-up CT 
(D, E) after treatment showed multifocal consolidation and GGO in both the lungs, and a small amount of left pleural effusion (white arrow) is observed. 
COVID-19 = coronavirus disease 2019, CT = computed tomography, GGO = ground glass opacity.
B CA
Fig. 4. A 52-year-old female with severe COVID-19 pneumonia. She had a history of hypertension and dementia. An initial chest CT scan on the day of admission 
shows focal subpleural consolidation (black arrow) with ground-glass opacity at the right lower lobe superior segment (A). A small amount of right pleural 
effusion is also noted (B; white arrow). One segment was involved, and the CT score was 1. Pneumonia is seen aggravated on the follow-up chest radiograph nine 
days after the initial CT (C). Peripheral oxygen saturation decreased to 92%, and 2 L nasal prong oxygen therapy was initiated. 
COVID-19 = coronavirus disease 2019, CT = computed tomography.
crazy-paving appearance (OR, 2.19; 95% CI, 1.01–4.78, P = 0.048) and CT score > 5 (OR, 4.81; 
95% CI, 2.28–10.13, P < 0.001) were all statistically significant factors to predict worsening 
to severe COVID-19. Other clinical factors including age older than 77 years (OR, 13.33; 
95% CI, 6.02–29.53; P < 0.001); underlying disease including hypertension (OR, 3.89; 95% 
CI, 1.89–8.01; P < 0.001), cardiovascular disease (OR, 3.03; 95% CI, 1.09–8.40, P = 0.033), 
neurologic disease (OR, 7.57; 95% CI, 3.18–18.02; P < 0.001), and malignancy (OR, 3.39; 95% 
CI, 1.10–10.40; P = 0.033); and abnormal laboratory finding including decreased ALC (OR, 
3.12; 95% CI, 1.52–6.42; P = 0.002), elevated CRP (OR, 6.77; 95% CI, 3.10–14.78; P < 0.001) 
and elevated LDH (OR, 5.15; 95% CI, 2.44–10.87; P < 0.001) were also significant factors that 
could predict severe COVID-19.
In multivariate analysis model 1, pleural effusion (adjusted OR, 8.96; 95% CI, 1.81–44.42; P 
= 0.007), CT score > 5 (adjusted OR, 3.70; 95% CI, 1.44–9.53; P = 0.007), and age > 77 years 
(adjusted OR, 9.96; 95% CI, 3.78–26.28; P < 0.001) were found to be significant prognostic 
factors of severe COVID-19. However, in multivariate analysis model 2, consolidation opacity 
and crazy-paving appearance were not found to be a significant prognostic factors of severe 
COVID-19.
The results of the univariate and multivariate regression analyses investigating the prognostic 
factors of the critical events are summarized in Table 4. In the univariate analysis, CT findings 
including pleural effusion (OR, 19.41; 95% CI, 4.65–81.02; P < 0.001), crazy-paving appearance 
(OR, 7.15; 95% CI, 1.94–26.33; P = 0.003) and CT score > 5 (OR, 8.32; 95% CI, 1.73–39.99; P = 
0.008) were significant predictors of the critical events. Consolidation opacity, however, was 
not found to be a significant prognostic factor for the critical events (OR, 3.25; 95% CI, 0.89–
11.84; P = 0.074). Other clinical factors including age > 77 years, underlying disease including 
neurologic disease and malignancy, abnormal laboratory findings including low ALC, high 
CRP, and high LDH were also significant contributing factors to critical events. In multivariable 
analysis model 1, pleural effusion (adjusted OR, 5.67; 95% CI, 1.04–30.8; P = 0.045) and CT 
score > 5 (adjusted OR, 7.29; 95% CI, 1.37–38.68; P = 0.020) were significantly predicted critical 
events along with age > 77 years (adjusted OR, 8.60; 95% CI, 1.80–41.0; P = 0.007). However, 
in multivariate analysis model 2, consolidation opacity and crazy-paving appearance were not 
found to be significant to predict the critical events.
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Fig. 5. Death of a 92-year-old male with COVID-19. He had a history of stroke, diabetes, and situs inversus totalis. Initial chest CT on the day of admission shows 
bilateral COVID-19 pneumonia (A, B), and a moderate amount of pleural effusion (C) is observed. All 20 segments were involved, and the CT score was 33. On the 
next day, peripheral oxygen saturation decreased by 90%. The patient refused active treatment or resuscitation, and died after 15 days due to respiratory failure. 
COVID-19 = coronavirus disease 2019, CT = computed tomography.
DISCUSSION
In this retrospective cohort study, we found that the presence of a pleural effusion and a 
CT score higher than 5 at the time of admission were prognostic independent factors for 
COVID-19, along with other known clinical factors such as an older age (> 77 years) and a high 
CRP (> 0.5 mg/dL). Although consolidation opacity was frequently observed in patients in 
the severe group, it was not found to be a predictor of poor prognosis in this study.
Pleural effusion has been found to be rare in COVID-19 pneumonia.16-18 Also, pleural effusion 
was observed only in 13 patients (4.6%) and majority of them (10/13, 76.9%) were severe 
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Table 3. Univariate and multivariate logistic regression analyses were performed to investigate clinical and CT imaging factors related to severe disease in 
coronavirus disease patients
Variables Univariate analysis Multivariate analysis
Model 1 Model 2
OR (95% CI) P value Adjusted OR (95% CI) P value Adjusted OR (95% CI) P value
Age > 77 yr (vs. age ≤ 77 yr) 13.33 (6.02–29.53) < 0.001 9.96 (3.78–26.28) < 0.001 15.40 (5.47–43.30) < 0.001
Male sex (vs. female) 1.88 (0.52–6.85) 0.340
Underlying disease
Hypertension 3.89 (1.89–8.01) < 0.001
Cardiovascular disease 3.03 (1.09–8.40) 0.033
Neurologic disease 7.57 (3.18–18.02) < 0.001
Malignancy 3.39 (1.10–10.40) 0.033
CT findings
CT score, > 5 4.81 (2.28–10.13) < 0.001 3.70 (1.44–9.53) 0.007
Pleural effusion 22.03 (5.64–86.06) < 0.001 8.96 (1.81–44.42) 0.007
Consolidation with or without GGO (vs. only GGO 
pneumonia or no pneumonia)
2.34 (1.15–4.76) 0.019 1.46 (0.54–3.95) 0.455
Crazy paving appearance 2.19 (1.01–4.78) 0.049 1.51 (0.56–4.07) 0.412
Laboratory findings
Absolute lymphocyte count, < 1,320 cells/µL 3.12 (1.52–6.42) 0.002
CRP, > 0.5 mg/dL 6.77 (3.10–14.78) < 0.001 4.15 (1.62–10.60) 0.003 4.26 (1.56–11.60) 0.005
LDH, > 474 U/L 5.15 (2.44–10.87) < 0.001
CT = computed tomography, OR = odds ratio, CI = confidence interval, GGO = ground glass opacity, CRP = C-reactive protein, LDH = lactate dehydrogenase.
Table 4. Univariate and multivariate logistic regression analyses were performed to investigate clinical and CT imaging factors related to critical events (ICU 
admission and death) in coronavirus disease patients
Variables Univariate analysis Multivariate analysis
Model 1 Model 2
OR (95% CI) P value Adjusted OR (95% CI) P value Adjusted OR (95% CI) P value
Age, > 77 yr (vs. age ≤ 77 yr) 16.26 (4.01–65.92) < 0.001 8.60 (1.80–41.0) 0.007 19.02 (4.08–88.67) < 0.001
Male sex (vs. female) 0.76 (0.33–1.75) 0.517
Underlying disease
Hypertension 1.54 (0.42–5.60) 0.513
Cardiovascular disease 3.28 (0.65–16.53) 0.151
Neurologic disease 11.18 (3.00–41.61) < 0.001
Malignancy 8.41 (1.95–36.30) 0.004
CT findings
CT score, > 5 8.32 (1.73–39.99) 0.008 7.29 (1.37–38.68) 0.020
Pleural effusion 19.41 (4.65–81.02) < 0.001 5.67 (1.04–30.8) 0.045
Consolidation with or without GGO (vs. only GGO 
pneumonia or no pneumonia)
3.25 (0.89–11.84) 0.072 1.87 (0.40–8.70) 0.427
Crazy paving appearance 7.15 (1.94–26.33) 0.003 4.27 (0.96–19.00) 0.057
Laboratory findings
Absolute lymphocyte count, < 1,320 cells/µL 4.19 (1.06–16.56) 0.041
CRP, > 0.5 mg/dL 19.69 (2.46–157.94) 0.005
LDH, > 474 U/L 5.05 (1.27–20.01) 0.021
CT = computed tomography, OR = odds ratio, CI = confidence interval, GGO = ground glass opacity, CRP = C-reactive protein, LDH = lactate dehydrogenase.
patients. We found that pleural effusion is the best prognostic factor (adjusted OR, 8.96; 
P = 0.007) to predict the severity of COVID-19 compared to opacity or the appearance of 
pneumonia. In the case of the Middle East respiratory syndrome (MERS) and SARS, pleural 
effusion has also been reported to be a significant prognostic factor.19-22 Interestingly, before 
progressing to severe pneumonia, pleural effusion was observed only in small amounts. As 
shown in Figs. 3 and 4, there was a small amount of effusion and the pneumonia was localized. 
Nevertheless, the patients progressed to severe pneumonia in the follow-up. Therefore, we 
suggest that, even though the amount of effusion in COVID-19 pneumonia patients is small, 
careful monitoring and early appropriate treatment is needed since this is a sign of progress 
toward a severe case. A previous animal model study reported a pleural effusion resulting from 
alveolar edema in severe MERS pneumonia.23 However, the exact cause and mechanism of 
the development of effusion in COVID-19 has not yet been investigated. Future studies on the 
pathophysiology of pleural effusion development in COVID-19 pneumonia are needed.
The CT score is another prognostic imaging factor which directly reflects the extent of 
pneumonia. Diffuse involvement of pneumonia is also a previously known prognostic factor 
in MERS and SARS pneumonia.24 According to a recent study, the aerated lungs less than 
< 73% is a predictor of ICU admission and death.25 Therefore, quantifying the pneumonia 
burden using the CT score, a quantification software, or even roughly by using the number 
of lobes or segments, would help classify the severity of patients.25 However, considering 
the progression of COVID-19 pneumonia, the extent of pneumonia on CT scans can differ 
considerably depending on the timing of the CT scan as in our cases (Figs. 3 and 4). Previous 
studies reported that 56% of the CT scans were normal at the early phase (0–2 days after 
symptom onset), and abnormal CT findings became more frequent at 6–11 days after 
symptom onset.26,27 In this study, we analyzed the CT scans taken at the time of admission in 
an early phase of the disease. Although a CT score above 5 at the time of admission does not 
necessarily indicate diffuse pneumonia, it should not be overlooked and the patient should be 
monitored carefully to check the progression of the severe pneumonia.
This study found that opacity in pneumonia was not a significant predictor of COVID-19 
severity, although consolidation and a crazy-paving appearance were significantly common in 
the severe group than in the non-severe group. Other studies also reported that consolidation 
was seen frequently in patients with an adverse outcome.8,9 However, our study suggests 
that the extent of pneumonia and presence of effusion are more important factors than 
the opacity itself. In the non-severe cases (Fig. 2), patients who showed pneumonia with 
consolidation on initial CT scans had a non-severe disease course. Therefore, the extent 
of pneumonia (CT score > 5) and presence of pleural effusion on CT scans at the time of 
admission are ominous signs, especially in patients of an older age with rising CRP.
There are several limitations in this study. First, this was a retrospective single center study 
with a relatively small number of patients included. Second, the sample size of the severe 
group and critical events were relatively small, therefore, further studies with more patient, 
especially severe patients are needed. Third, we did not consider treatment information in 
this study. Fourth, although the CT was taken at the time of admission, the symptom period 
from the onset to the time of admission was in the range of 2–13 days among the patients.
In conclusion, pleural effusion and a higher CT score on CT scan at the time of admission 
are imaging predictors of poor prognosis in COVID-19 patients. These CT findings may help 
triage COVID-19 patients in resource-constrained environments.
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